PTPRD and cancer: Most importantly, the univariate (HR = 0.585, 95% CI: 0.472-0.725, P < 0.0001) and multivariate (HR = 0.703, 95% CI: 0.557-0.887, P < 0.003) COX analyses showed that patients with PTPRD/PTPRT mutations had a better prognosis than WT patients, indicating that PTPRD/PTPRT mutations are an independent prognostic factor in pan-cancer patients treated with ICIs (Table 2).